Introduction
Accumulating evidence has suggested that the transformation of a normal plasma cell into a malignant myeloma cell is a multiple-step process (Bergsagel and Kuehl, 2001; Hallek et al., 1998) . Genotypic changes are found in 60% of patients at diagnosis by conventional karyotyping and in up to 90% of patients by FISH analysis. Some of these genetic abnormalities have been identified. Overall there is a rearrangement of the 14q32 (IgH) locus in 60% of patients, c-myc in 15 -50%, cyclin D1 in 20%, FGFR3 in 10%, cyclin D3 in 5%, as well as other genes not yet identified. In addition, 40% of multiple myeloma (MM) cases display monoallelic deletions of chromosome 13 in association with the loss of one retinoblastoma allele. Mutations of the K-ras and N-ras genes are found in 50% of the patients at diagnosis and p53 monoallelic loss in 20%. Phenotypic changes have also been described such as the loss of CD19 and aberrant expression of CD56. Moreover, the bone marrow environment is highly activated in MM, as evidenced by a high stimulation of neoangiogenesis, a production of myeloma cell growth factors such as IL-6 (Klein et al., 1995) , a production of IL-6 inducers such as IL-1 (Costes et al., 1998) , and stimulation of bone resorption. This abnormal hyperactivation of the bone marrow environment in patients with MM is the result of synergistic interactions between the malignant plasma cells and specific cells in the tumor environment, likely involving various pathways of intercellular communication.
The portrayal of this complex alteration of the cellular circuitry and cellular behavior in myeloma cells will best be apprehended by the use of DNA microarrays. Indeed, gene-expression profiling using microarrays allows the simultaneous analysis of multiple markers and is thus an ideal tool to study the global changes that drive a normal cell to malignancy (Alizadeh et al., 2000; Thykjaer et al., 2001) . We recently used nylon cDNA macroarrays and identified cytokines and cytokine receptors overexpressed in human myeloma cell lines (HMCL) compared to their autologous, EBV-transformed B cell lines (De Vos et al., 2001) . The recent description by our group of a procedure allowing the generation of nonmalignant polyclonal plasma cells in patients with myeloma provides us with the opportunity to compare the gene expression profile of malignant plasma cells directly with their normal autologous counterpart (Tarte et al., 2002) . Oligonucleotide microarray analysis between myeloma cells, polyclonal plasma cells, and B cells can identify genes whose expression was restricted to plasma cells, i.e., plasma cell genes (Tarte et al., 2002) . This technique also opened the way to a molecular classification of this heterogeneous disease . In this study, we have analysed genes that are overexpressed or underexpressed in myeloma cells compared to normal plasma cells. Among the numerous genes that have a higher expression level in malignant plasma cells, we have focused our study on a few genes that encode for proteins that could be involved in myeloma biology or could be potential therapeutic targets.
Results and Discussion

Unsupervised clustering
The myeloma samples comprised highly-purified myeloma cells (495%) from six patients with medullary MM (MM1-MM6), from three patients with plasma cell leukemia (PCL1 -PCL3) (Table 1) , and eight myeloma cell lines . The eight normal plasma cell samples were in vitro-generated polyclonal plasmablastic cells (PPC1 -PPC7) and highly purified plasmablasts (499%) from one patient with reactional polyclonal plasmacytosis (RP). The gene expression profiling of the samples was determined with Affymetrix HuGeneFL arrays (6800 genes) and the Affymetrix files are available as supplementary data (http://www.u475.montp.inserm.fr/BK/SupplementalData.htm). Data were processed as indicated in Materials and methods and 3874 genes were retained for analysis. The hierarchical clustering method delineated two major clusters: one cluster comprising the in vitro-generated PPC and the RP sample that was termed the PPC cluster and a myeloma cluster ( Figure  1a ). Of note, the three PPCs obtained from myeloma patients (i.e., PPC4, PPC5, and PPC6) and from healthy donors (i.e., PPC1, PPC2, and PPC3) segregated together and were intermingled. The myeloma cluster was subsequently divided into two subclusters, a primary myeloma cell cluster comprising MM1 -MM6 and PCL1 and PCL3 (subsequently called the MM cluster) and a myeloma cell line cluster, which comprised all HMCLs included in this study and primary myeloma cells from one patient with PCL -PCL2 (termed the HMCL cluster). Interestingly, we have been able to grow PCL2 cells in vitro -thereby generating a new IL-6-dependent HMCL (XG-19) -but not PCL1 or PCL3 cells. Principal component analysis (PCA) was used as a second unsupervised method to classify samples. The first three principal components retained 46.6% of the total variance and allowed us to display our 25 samples in a space with three dimensions (Figure 1b) . In complete agreement with the hierarchical clustering, the PCA method delineates three clusters of samples: PPC, MM (MM1 -MM6, PCL1 and PCL3), and HMCL (HMCL and PCL2). Thus both average linkage clustering and PCA recognized the different biologically relevant sample groups, suggesting that the oligonucleotide arrays could indeed apprehend the molecular differences that distinguish normal plasma cells from myeloma cells.
Comparison of gene expression between malignant and normal plasma cells
Gene expression between malignant and normal plasma cells was compared with the Mann -Whitney nonparametric statistical test. Out of the 3874 genes retained in the analysis, 250 were significantly (P40.05) overexpressed in malignant plasma cell samples compared to normal plasma cells, with a ratio of mean expression values 52. Similarly, 159 genes were underexpressed in malignant plasma cell samples, with a ratio of mean expression values 40.5. Tables 2 and 3 (shown as  supplementary information, http://www.u475.montp.inserm.fr/BK/SupplementalData.htm) list these 409 genes that are significantly overexpressed or underexpressed in MM, respectively. In the following, we have focused on genes that validated our microarray data, could be of major importance for the emergence of the malignant plasma cell clone, or could be potential therapeutic targets. These genes and their expression are shown in Figure 2 .
Altered expression of cell cycle genes in myeloma samples
Cyclin D1 Cyclin D1 is one of the most differentially expressed genes between normal and malignant plasma cells ( Table 2 ). The up-regulation of this oncogene is in good agreement with the recurrent t(11;14)(q13;q32) translocation observed in myeloma cells, involving the immunoglobulin heavy (Ig H) chain gene and the cyclin D1 gene, whereas cyclin D1 is not expressed in normal hematopoiesis and lymphopoiesis (Bergsagel and Kuehl, 2001 ). The microarray results were validated by the known cytogenetics of our cell lines since a t(11;14)(q13;q32) translocation has been documented in the XG-1 and XG-5 HMCLs (Raynaud et al., 1993) , and a more complex chromosome 11 abnormality, der(11)t(1;3;11), was reported in XG-6 by spectral karyotyping (Rao et al., 1998) . The Affymetrix microarray data were also in good agreement with the WB analysis that demonstrated a strong cyclin D1 expression in XG-1, a weak expression in XG-5 and Figure 3a ).
Myc and myc partners
The Affymetrix microarrays showed a 7.5-fold overexpression of the c-myc gene in myeloma cells compared to normal plasma cells, which confirms the frequent overexpression of the c-myc oncogene in myeloma cells reported by others (Shou et al., 2000) . The low expression of the c-myc gene in normal plasma cells is in agreement with the reported silencing of this gene during normal plasma cell differentiation by PRDI-BF1. We have previously found that these in vitro-generated normal plasma cells expressed PDRI-BF1 (Tarte et al., 2002) . Using WB, we have confirmed that eight out of eight of the HMCLs overexpressed the c-myc protein, unlike normal plasma cells (Figure 3b ). The very high c-myc gene and protein expression in RPMI8226 cells is in agreement with a reported c-myc-IgLl rearrangement in this HMCL (Avet-Loiseau et al., 2001 ). In addition, we found an overexpression in myeloma samples of three other genes, which either encode for proteins that cooperate with c-myc during oncogenesis (BMI-1 and MSSP, c-myc single-strand binding protein) or are essential to c-myc function (GCN5L2, general control of amino-acid synthesis-like 2). Regarding BMI-1, we have confirmed by WB a higher expression in five out of eight myeloma samples as compared to normal plasma cells (Figure 3c ). BMI-1 is an oncogene that was first identified because of its cooperation with cmyc for lymphoid transformation in vivo (van Lohuizen et al., 1991) . A recent study has revealed that BMI-1 is a transcription repressor that targets the ink4a locus, which encodes the p16 protein and that BMI-1 cooperates with c-myc by repressing p16 and P19/ ARF. Of note, the p16 protein is often absent in myeloma cells (Ng et al., 1997) . Though a promoter hypermethylation has been invoked, our data suggest that BMI-1 could contribute to p16 silencing in MM. The second myc partner gene upregulated in myeloma samples is MSSP. MSSP is a myc-mediated transcription modulator and stimulates the cooperative transforming activity of c-myc with ras. The general up-regulation of c-myc and the frequent activating ras mutation in myeloma could thus see their transforming properties enhanced in myeloma cells by the overexpression of MSSP. Finally, the third c-myc partner gene upregulated in myeloma samples codes for GCN5, a histone acetyltransferase which plays an essential role in the transcriptional activity of c-myc. Overall, our microarray data highlight a pivotal role for an up- regulation of the c-myc pathway in MM. It is noteworthy that a deregulation of the c-myc gene is an obligatory oncogenic event to create a malignant plasma cell tumor in mice (Potter and Wiener, 1992) .
Other cell cycle genes We found that the CDC34 gene was up-regulated in 11 out of 14 MM samples. Of note, this gene has already been reported to be upregulated in acute lymphoblastic leukemia and hepatocellular carcinomas (Tanaka et al., 2001) . CDC34 is a ubiquitin-conjugating enzyme that appears to play a particularly important role in the control of the cell cycle in budding yeast and Xenopus (Michael and Newport, 1998) . CDC34 is also probably involved in the regulation of the cell cycle of mammalian cells, given its high conservation in eukaryotic cells. Cut-like 1 (CUTL1), which has a demonstrated role as an inhibitor of the p21 cyclin kinase inhibitor (Coqueret et al., 1998) , was also overexpressed in MM samples as compared to PPC. Finally, analysis of genes downregulated in MM samples identifies the tumor suppressor retinoblastoma (Rb). This lower expression could be related to the high incidence of monoallelic deletion in MM cells (Juge-Morineau et al., 1995) . WB confirmed the higher level of Rb protein in normal plasma cells compared to MM cells (Figure 3d ). Thus, though we compared our MM samples to nonmalignant plasmablasts which still retain a high mitotic index (Tarte et al., 2002) , in malignant plasma cells we found an altered expression pattern of several genes involved in cell cycle regulation.
Altered expression of apoptosis genes in myeloma samples
Gene alterations leading to increased cell survival are frequent in cancer. A striking difference between normal and malignant plasma cells is the up-regulation of the anti-apoptotic Bcl-2 gene and the downregulation of the pro-apoptotic BIK (Bcl2-interacting killer) gene in MM samples. A high expression of Bcl-2 Figure 2 Genes differentially expressed between normal and malignant plasma cells. Visualization by Treeview of genes that are significantly (except Tyro 3) over-or under-expressed in malignant plasma cell samples compared to normal plasma cell samples and that are discussed in the text. Color code for samples is as in Figure 1 . Each value represents the difference from the gene mean and is depicted according to the color scale shown at the bottom (76 to 6 on a log base 2 scale). The P-value obtained by the Mann -Whitney test and the fold change is indicated for each gene. 1, proliferation; 2, apoptosis; 3, transduction; 4, metabolism; 5, bone remodeling; 6, cancer/testis antigens in MM is a well known feature of malignant plasma cells (Pettersson et al., 1992) . Since the balance between pro-and anti-apoptotic members of the Bcl-2 family participates in the cell fate decision between survival and apoptosis, modifications of Bcl-2 and BIK expression are likely linked to an enhanced survival of malignant plasma cells. In addition, several genes whose products have been described as conferring resistance to apoptosis are also up-regulated in MM samples: IER3, heat shock protein 27 (HSP27), and c-IAP2. IER3 is a NF-kB-induced protein protecting from TNF-a-or FAS-induced apoptosis (Wu et al., 1998) . HSP27 is a heat shock protein whose overexpression protects against various apoptotic stimuli, including growth factor removal, at least partly by interacting with cytochrome c and preventing cytochrome-c-mediated activation of procaspase-9 (Bruey et al., 2000) . An up-regulation of HSP27 has also been observed in prostatic carcinoma and correlates with a poor clinical prognosis (Cornford et al., 2000) . c-IAP2 is a member of the IAP family, which has antiapoptotic properties by inhibition of caspase. Collectively, we found an up-regulation of genes in myeloma samples whose protein products should cooperate to increase myeloma cell survival and drug resistance.
Altered expression of transduction genes in myeloma samples
ABL tyrosine kinase The expression of the tyrosine kinase ABL, involved in the Philadelphia chromosome in chronic myeloid leukemia, is up-regulated in myeloma samples. This is of particular interest since a constitutive ABL and myc activation can induce plasmacytomas in BALB/c mice (Largaespada et al., 1992) . We took advantage of the recently developed ABL kinase inhibitor STI 571 to test whether ABL kinase activity is important in MM cell survival or proliferation. We found that the STI 571 inhibitory concentration necessary to obtain a 50% inhibition in MM cell proliferation (IC50) is rather high (5 mM in XG13 to 20 mM in XG1) compared to the BCR-ABL expressing cell line K562 (0.5 mM) (data not shown). As a potential link between ABL and gp130 IL-6 transducer pathways through STAT3 phosphorylation was suggested in murine ABL/myc plasma cell tumors (Hilbert et al., 1996) , we evaluated the combined effect of STI 571 and anti-IL-6 antibodies on myeloma cell proliferation. When used alone, an intermediate concentration of STI 571 (3 mM) or of the B-E8 anti-IL-6 antibody (0.03 mg/ml) resulted in a minor decrease in myeloma cell proliferation (36% and 26%, respectively), whereas the combination of STI 571 (3 mM) and B-E8 antibody (0.03 mg/ml) induced a marked (59%) and significant (P=0.0004) inhibition (Figure 4a) . Thus, when the available IL-6 signal becomes limiting, the kinase activity of ABL turns out to be essential. As a first clue for the molecular explanation of this cooperation between these two signaling pathways, we observed that IL-6 stimulation induced ABL phosphorylation in myeloma cells (Figure 4b ). This is the first model in which IL-6 was shown to induce ABL phosphorylation. Further studies are necessary to understand the role of ABL in the myeloma cell survival mediated by gp130 IL-6 transducer activation. We have shown that anti-IL-6 mAb can block myeloma cell proliferation in patients with terminal disease (Klein et al., 1991) . More recently, we have shown that these anti-IL-6 antibodies might improve shown. NS, nonspecific; pprb, phosphorylated Rb; dprb, dephosphorylated Rb. In PPC, a 55 Kd band was usually detected due to the crossreaction of the polyclonal goat anti-mouse IgH with human IgH. This band is not detected in MM cells that produce a monoclonal Ig at a low level compared to normal plasma cells (Klein et al., 1995) the overall survival of patients treated with high-dose chemotherapy (unpublished results). The present data suggest that the ABL kinase inhibitor STI 571 could have clinical benefit in combination with anti-IL-6 mAb, at least in the patients with a demonstrated overexpression of the ABL gene in myeloma cells.
Tyro3 receptor tyrosine kinase (RTK) family In a previous study with ATLAS macroarrays, RT -PCR, and WB, we found an overexpression in myeloma cells of Tyro3, an oncogenic receptor tyrosine kinase (RTK) (De Vos et al., 2001) . Tyro3 belongs to a family of three RTK members, Tyro3 (also termed Rse, Sky, Tif, or Dtk), MER (also termed Eyk) and Axl (also termed Ufo or Ark), which share the same ligand, GAS6. Likely due to a lack of sensitivity of the Tyro3 probes in the HuGeneFL chip, we only observed a significant expression of Tyro3 by Affymetrix microarray in the XG-6, -7, and -14 HMCLs (Figure 2 ), which are the samples expected to have the highest Tyro3 expression according to our previous immunoblot data (De Vos et al., 2001) . However, we observed that a second member of the tyro3 RTK family, MER, was upregulated 5.1-fold in MM samples compared to PPC. The third tyro 3 RTK family member, Axl, was not included in our 3874-probe set list. Thus, using various techniques, we found that two members of the tyro 3 TRK family were overexpressed in myeloma cells compared to normal plasma cells. These findings may be of importance because tyro3 is an oncogene in murine fibroblasts and we recently found that both normal and tumor plasma cells highly express GAS6, the common ligand of the Tyro3 RTK family, as compared to B cells (Tarte et al., 2002) . Studying the role of an autocrine GAS6/Tyro3 receptor family loop in the function of myeloma cells is problematic due to the lack of commercially available reagents.
Other transducing elements RhoC is a small GTPase that is a transforming oncogene for human mammary epithelial cells. Its overexpression is associated with inflammatory breast cancer and with metastasis formation in melanoma (Clark et al., 2000; van Golen et al., 2000) . Our data point to a 8.5-fold increase in RNA expression in malignant plasma cells as compared to their nonmalignant counterpart. To our knowledge, RhoC has never been related to myeloma biology. Its high expression could contribute to inflammatory bone marrow and the high level of tumor dissemination in a majority of MM cases at diagnosis. We also note a higher expression of the NFKB2 gene in myeloma samples. NFKB2 is a member of the REL/NFKB family of transcription factors that was first cloned as an oncogene involved in a translocation with the IgH locus in lymphoid malignancies, including myelomas (Neri et al., 1991) . Two genes coding for pre-B cell proliferation enhancers were found up-regulated in myeloma samples: stromal interaction molecule 1 (STIM1) and pre-B-cell colony-enhancing factor (PBEF). These factors increase the IL-7-dependent proliferation of pre-B cells and could therefore play a role in B- The IL-6-dependent XG-14 HMCL was cultured without IL-6 for 24 h and restimulated with IL-6 (20 ng/ml) for 10 min. Anti-ABL immunoprecipitates were resolved by 7.5% SDS -PAGE, and phosphorylation of ABL was detected by immunoblotting with an anti-phosphotyrosine antibody. Blots were stripped and reprobed with an anti-ABL antibody lymphoid malignancies, including MM (Oritani and Kincade, 1996; Samal et al., 1994 
Altered expression of metabolism genes in myeloma samples
Cystathionine beta synthase (CBS) The oligonucleotide microarray analysis shows that the CBS gene, coding for an enzyme involved in methionine metabolism, is increased 16-fold in myeloma samples. The Affymetrix data were confirmed by RT -PCR ( Figure  5a ). Due to its localization on chromosome 21, CBS expression is increased in Down syndrome (DS) associated with trisomy 21, and this CBS overexpression could account for the higher sensitivity of DS acute myeloid leukemia blasts to ara-C (Taub et al., 2000) . Interestingly, we found a significant correlation (P=0.04) between CBS overexpression and ara-C sensitivity in our six IL-6-dependent myeloma cell lines (Figure 5b -d) . XG-1 cells were especially highly sensitive to ara-C with an IC50 around 0.6 nM, 10 000-fold lower than the plasma ara-C concentration achievable in vivo with clinical protocols (Taub et al., 1996) . This observation encourages reconsideration of the use of ara-c in the treatment of patients with MM. This drug did not show any clinical benefit in this disease while its toxicity was high (Kantarjian et al., 1984) . However, as the fraction of proliferating myeloma cells is low in patients with MM, a continuous administration mode could be interesting to induce an antitumor effect, at least in the subset of MM patients with CBS gene overexpression.
Phosphofructokinase isoform (PFKM)
The PFKM gene is overexpressed 10 times in MM samples. PFKM is a rate-limiting enzyme in glycolysis and should contribute to myeloma cell oncogenesis since cancer cells rely on glycolysis for energy, even in the presence of oxygen, a phenomenon called the Warburg effect. This increased PKFM gene expression and subsequent altered glycolysis in myeloma cells is likely related to the myc pathway deregulation discussed above. Indeed, PKFM gene expression can be induced by c-myc in fibroblasts (Osthus et al., 2000) . The possibility that the PKFM gene is a target of the deregulated c-myc pathway in myeloma cells is emphasized by the very tight correlation (Pearson's correlation coefficient=0.847, P=4.10 78 ) between c-myc and PFKM gene expression among the 25 samples.
Other metabolism genes Two genes with increased expression in myeloma samples encode enzymes involved in nucleoside metabolism and their overexpression has been linked to malignancy: the nucleoside triphosphate synthesis gene nonmetastatic cells 4 (NME4), which is detected in diffuse astrocytomas but not in normal brain tissue , and the purine metabolism gene guaninemonophosphate synthetase (GMPS), whose mRNA and protein expression are higher in leukemia cell lines and lymphoblastoid lines than in nontransformed, nonproliferating cells (Hirst et al., 1994) Genes involved in metastasis or bone remodeling Secreted protein acidic and rich cystein (SPARC) SPARC is a secreted, multifunctional, extracellular matrix glycoprotein which inhibits cell adhesion and activates MMP2. SPARC expression is linked to an invasive phenotype in glioblastomas and was shown to be necessary for metastasis of melanoma cells in vitro and in vivo (Ledda et al., 1997) . Thus SPARC could be related to the spreading of MM cells in vivo; the observation that this gene is more expressed in our cell lines than in primary myeloma samples is in agreement with this hypothesis (Figure 2 ).
Legumain and cystatin C Unexpectedly, the gene coding for the cystein protease legumain/PRSC1 was increased 12-fold in MM samples as compared to PPC. This gene was recently cloned as an inhibitor of osteoclast activity and bone resorption (Choi et al., 1999) , which seems counterintuitive in a bone destructive disease. However, cystatin C, the most potent inhibitor of cystein proteases including legumain, is one of the most highly up-regulated genes in MM samples (50-fold). We confirmed the microarray data by WB and immunohistochemistry for cystatin C and by RT -PCR for legumain (data not shown). One can speculate that legumain expression is a negative feedback loop arising in myeloma bone marrow where excessive osteoclast activity is occurring, but that myeloma cells disrupt this regulatory circuit by expressing cystatin C at a high level.
Cancer/testis tumor antigen genes
The expressions of MAGE A1, A2, and A3 as well as NY-ESO-1 and SSX2 genes were increased in MM samples. These genes have a normal expression restricted to testis but display an aberrant expression in numerous tumor types, including myeloma (PellatDeceunynck et al., 2000; Tarte et al., 2002) .
Conclusion
Despite recent molecular advances in the knowledge of MM, we are still far from a complete description of the biology of this cancer. This study demonstrates the power of the microarray technology to identify genes deregulated in malignant plasma cells provided that normal plasma cells can be obtained. We used in vitro generated plasmablastic cells, whereas in a recently published work, Zhan et al. (2002) used bone marrow plasma cells from healthy individuals. A quarter of the genes overexpressed in myeloma cells found in the present study were also identified in Zhan's study. The fact that the other genes were not retrieved in common may be explained by distinct statistical methods and different sources of normal plasma cells. Zhan et al. (2002) used only statistical tests to select genes differentially expressed between malignant and normal plasma cells. In the current study, we used a combination of one statistical test and the ratio of the mean expression in malignant and normal plasma cells. Indeed, a difference in expression for a given gene between malignant and normal plasma cells should be taken with caution if there is a significant P-value but only a minor change in the mean ratio. We chose a minimal ratio of 2 which was established as the approximate limit of sensitivity for Affymetrix oligonucleotides microarrays (reviewed by Su et al., 2002) . The source of normal plasma cells is also important. For instance, most proliferation and metabolism genes identified as myeloma genes in the study from were not found in our study because we used proliferating plasmablastic cells as a normal counterpart. On the other hand, we found several genes upregulated in myeloma cells that were genes also upregulated in mature normal bone marrow plasma cells and that are therefore indicators of plasma cell differentiation. The use of these two sources of normal plasma cells are therefore complementary. Overall our microarray data were confirmed by the differential expression of numerous genes according to published data, by western blot and by RT -PCR. Genes such as CBS and ABL code for enzymes that could be potential therapeutic targets with ara-c or STI571.
Materials and methods
Cell lines
XG-1, have been obtained in our laboratory and RPMI 8226 from the American Tissue Culture Collection. These HMCLs express cytoplasmic Ig and plasma-cell antigens (Ag) and lack the usual B-cell Ag (De Vos et al., 2001) . The HMCLs were grown in RPMI 1640 culture medium supplemented with 10% fetal calf serum (FCS) or X-VIVO 20 serum-free medium (Bio Whittaker, Walkersville, MD, USA) with or without 2 ng/ml of IL-6 (R&D Systems, Minneapolis, MN, USA). All cell lines were free of mycoplasma, as assayed by an ELISA kit (Roche, Meylan, France).
Primary cells
Malignant plasma cells were purified from six patients with MM and three patients with plasma cell leukemia (PCL) after Table 1 . One sample of polyclonal plasma cells was obtained from a patient with transient reactive plasmacytosis (RP), as defined by Jego et al. (1999) . Purification of plasma cells (495% plasma cells) was performed with the MI15 anti-CD138 mAb and anti-mouse IgG1 MACS Microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) as described (De Vos et al., 2001) . Seven samples of polyclonal plasmablastic cells were obtained by in vitro differentiation of peripheral blood B cells (PPC) from either healthy volunteers or from MM patients using a methodology we recently developed (Tarte et al., 2002) . The plasmablastic cells (CD38 ++ , CD20 7 ) were purified (499% purity) by highspeed cell sorting using a FACS Vantage Cell Sorter (Becton Dickinson, San Jose, CA, USA). These cells displayed a typical plasma cell morphology on cytological examination, secreted high levels of polyclonal Ig, and lacked the B cell markers CD20, CD21, CD22 and CD23.
cRNA preparation and GeneChip hybridization RNA was extracted using the RNeasy Kit (Quiagen, Valencia, CA, USA). cRNA was prepared as described previously (Thykjaer et al., 2001) , except that total RNA was used as starting material and hybridized to HuGeneFL GeneChip oligonucleotide arrays (Affymetrix, Santa Clara, CA, USA). These arrays contain 7070 sets of oligonucleotide probes representing 6800 full-length human sequences.
Data collection
The probe arrays were scanned at 560 nm using a confocal laser-scanning microscope with an argon ion laser as the excitation source (Hewlett-Packard GeneArray Scanner G2500A). We captured primary data using MAS 4.0 software, resulting in a single raw value for each probe set (average difference) based on the mean of the differences between the hybridization intensity for the perfect match features and the mismatch features for a particular gene. Data from each different array experiment were scaled to 1500 by the Affymetrix GeneChip software in order to account for differences in global chip intensity. Affymetrix files are available as supplementary data (http://www.u475. montp.inserm.fr/BK/SupplementalData.htm). This dataset was floored to 200, since discrimination of expression changes in this low range can not be performed with high confidence.
Statistical analysis
We analysed 3874 genes among the 25 samples, with at least three absolute calls defined as 'present' by the GeneChip software. In order to evaluate how the 25 samples were grouped together according to the similarity of their gene expression profiles, we used two separate unsupervised clustering algorithms: a hierarchical clustering with the average linkage method and an uncentered correlation, and principal component analysis (PCA). For hierarchical clustering, data were log transformed, median centered, and processed with the CLUSTER and TREEVIEW software packages (Eisen et al., 1998) . For PCA, data were log transformed, median centered, and processed with the JExpress 1.1 program (Dysvik and Jonassen, 2001) . Given the high computational task required for this analysis, we reduced the gene number by selecting the 1500 genes with the highest variation coefficient among the 25 samples. The first three principal components retained 46.6% of the total variance of this dataset. We then determined the genes whose expression significantly (P 40.05) varied between normal and malignant plasma cells using the nonparametric MannWhitney test. We retained only genes that had a ratio of mean values between these two categories 52 or 40.5. The Mann -Whitney test, as well as the Pearson and Spearman correlation calculations, were performed with the SPSS software (SPSS Inc., Chicago, IL, USA).
Western Blot
Western blots (WB) were done as previously described (de Vos et al., 2001) . Anti-cyclin D1 monoclonal antibody was purchased from Upstate Biotechnology (Lake Placid, NY, USA), anti-Rb from Pharmingen (San Diego, CA, USA), anti-STAT3 from Transduction Laboratories (Lexington, KY, USA), anti-Mer goat polyclonal antibody from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-BMI-1 F6 monoclonal antibody was a kind gift from Maarten van Lohuizen and anti-c-myc 9E10 monoclonal antibody from Jean-Marie Blanchard.
Reverse transcriptase-polymerase chain reaction
Reverse transcription and PCR were done as previously described (De Vos et al., 2001) . The following primers were used for CBS: 5'-AGG ACG GTG GTG GAC AAG TGG TTC AAG AGC AA (sense) and 5'-TGA CCA CCC CGA ACA CCA TCT GCC GCT GAC TG (antisense) (Taub et al., 1999) . The size of the CBS PCR product was 656 bp. Annealing temperature was 608C and the number of cycle 35.
Proliferation assay for myeloma cell lines
Cells were washed twice with RPMI 1640 culture medium, incubated for 3 h at 378C in RPMI 1640 culture medium and 10% FCS, and washed again. They were then cultured at 10 4 cells per well in RPMI 1640 culture medium and 10% FCS with or without IL-6, and with various concentrations of STI571, provided by Novartis Pharma (Basel, Switzerland), B-E8 monoclonal anti-IL-6 antibody (mAb), provided by John Wijdenes (Diaclone, Besanc¸on, France), or 1-b-Darabinofuranosylcytosine (ara-C), in 96-well flat-bottomed microplates for 4 days. Tritiated thymidine (0.5 mCi, 25 Ci/ mM, NEN, Paris, France) was added for the last 12 h of culture and tritiated thymidine incorporation was determined as reported previously (De Vos et al., 2000) . The ara-C concentration that inhibited cell growth by 50% (IC 50 ) is the mean of three independent experiments.
